RIGI and cancer: Firstly, we found that the number of monoclonal formations was inhibited in DDX58-shRNA compared to the control group (Figure 4A), and the similar results were further confirmed in DDX58-KO cells (Figure 4B), indicating that DDX58-shRNA and DDX58-KO led to impaired cancer cell growth and proliferation.